StoneX Group’s Outlook Therapeutics OTLK Stock Holding History

StoneX Group’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-13,122	Closed	-$2.7K	–	1539
2026 Q1	$2.7K	Buy	+13,122	New	+$5.67K	﹤0.01%	898

Other funds holding OTLK

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

GWM

Gilpin Wealth Management Denver, Colorado $145M AUM

StoneX Group's OTLK Position: Q2 2026 in Review

StoneX Group sold out of Outlook Therapeutics (OTLK) in Q2 2026, closing a stake of 13,122 shares — an estimated $2.7K sold.

StoneX Group first reported a position in OTLK in Q1 2026 and held it in 1 quarter. The position peaked at $2.7K in Q1 2026. 69 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.

StoneX Group reported no remaining Outlook Therapeutics position as of Q2 2026 after selling out during the quarter.
StoneX Group sold 13,122 Outlook Therapeutics shares in Q2 2026, an estimated $2.7K.
StoneX Group first reported a position in Outlook Therapeutics in Q1 2026 and held it in 1 quarter.
StoneX Group's Outlook Therapeutics position peaked at $2.7K in Q1 2026.
69 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.

Based on StoneX Group's 13F filing for Q2 2026, filed 12 Aug 2026.